It was a short, sweaty week complete with fireworks....
RNAi is H-O-T:
Li'l biotech Alnylam dipped its fingers into another Big Pharma cookie jar this week as it brokered a $1 billion deal with Roche. (Novartis is its other partner.) This is the second deal in the past week in which a big drugmaker has plunked down a lot of change for RNA interference, or RNAi, a method of silencing harmful genes that is widely touted as drug research's next big thing. Last week, AstraZeneca paid $405 million to Silence Therapeutics; last year, Merck doled out $1.1 billion for Sirna Therapeutics....
Thailand's Patent-Busting Tear:
Thailand is ordering 2 million doses of generic Plavix from India after deeming the discounts for the blood thinner from owners Bristol-Myers Squibb and Sanofi-Aventis too stingy. Playing hardball with patents is nothing new to Thai health officials, who even forced Abbott's stubborn Miles White to say uncle in the face of compulsory-license threats over HIV drug Kaletra's price tag....
Speaking of Which:
Brazil agreed to Abbott's offer to slice the price of Kaletra by 29.5 percent in return for not resorting to cheapie knockoffs. The lower price for the first-line blockbuster will save Brazil about $10 million a year for its AIDS treatment program, which promises all people with HIV free treatment. In May, Merck's Sustiva patent was shredded by the South American tiger....
Black Box Off Antidepressants?
FDA may remove the teen-suicide stigma from Prozac and its pals amid growing noise from shrinks that the warning issued three years ago has scared off docs from treating kids for depression. The number of scrips for pediatric depression fell by more than 50 percent between 2003 and 2005, while teen-suicide seem to be rising by record numbers, a new study says....
New Drug News:
FDA OK'd the first-ever skin patch for Alzheimer's, the Exelon Patch from Novartis (an old drug with a new delivery). Etravirine, Tibotec's second treatment in as many years for drug-resistant HIV, is heading to FDA for accelerated approval....Barr Labs got the go-ahead to market a generic version of Dostinex for Parkinson's....
Another Chinese Head Rolls:
A former high-up at China's FDA has been sentenced to death for corruption and approving bogus drugs. Cao Wenzhuang was convicted of pocketing over $300,000 in bribes from two drug firms and "undermining public confidence in an agency safeguarding the nation's health." The trial was followed by the execution of his colleague, Zheng Xiaoyu, convicted on similar charges.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.